Boston, MA 06/18/2013 (wallstreetpr) – The share prices of Delcath Systems Inc. (NASDAQ:DCTH) had declined by 9.15 percent to close at $0.491 per share for the end of last trading session on Monday. The shares of the company had been trading in the range of $0.48 to $0.62 per share during the day. The shares of Delcath Systems Inc. (NASDAQ:DCTH) had recorded 52 week high price level of $2.38 per share and 52 week low price level of $0.58 per share.
Delcath Systems Inc. (NASDAQ:DCTH) is primarily focused on the field of oncology and initially concentrates on the cancer in liver. It is a development stage, specialty pharmaceutical and medical device company with the present focus on development and clinical study of Delcath Chemosaturation system. This system being developed by Delcath Systems Inc. (NASDAQ:DCTH) allows the administration of concentrated regional chemotherapy by isolating the circulatory system of the targeted organ. Once the organ is isolated, the Delcath chemosaturation system delivers doses of chemotherapeutic agents directly to the liver. The Delcath chemosaturation system involves a series of three catheter insertions, each of which is placed percutaneously through interventional radiology techniques. The procedure is minimally invasive and repeatable allowing for multiple courses of treatment with chemotherapeutic drugs.
The shares of Delcath Systems Inc. (NASDAQ:DCTH) had recently been declining in prices with higher trading volumes. The company had witnessed the trade of 7.10 million shares on Monday, while the average trading volume is at 2.46 million shares per day.
Delcath Systems Inc. (NASDAQ:DCTH) presently holds 96.73 million shares outstanding in the market with an institutional ownership of 11 percent of its holdings.